Ads
related to: remicade biosimilar- XELJANZ® Co-Pay Savings
Learn About The Co-Pay Savings
Program & Eligibility Requirements
- Doctor Finder Tool
Find A Healthcare Provider Near You
On The Rx XELJANZ® Patient Site
- Connect With XelSource
Call XelSource To Learn About
Potential Savings For Rx XELJANZ®
- Prescribing Info
See Full Prescribing Info And
Boxed Warning For Rx XELJANZ®
- HCP Resources
Visit The Official HCP Site
To Learn More About Rx XELJANZ®
- Patients In Focus
Hear From Real Rx XELJANZ® Patients
To Learn About Their Experiences
- XELJANZ® Co-Pay Savings
Search results
Amgen (AMGN) Posts Positive Data from Soliris' Biosimilar Study
Zacks via Yahoo Finance· 2 years agoAmgen's (AMGN) phase III study evaluating ABP 959, a biosimilar candidate to Soliris for treating...
Springfield man says his ulcerative colitis was under control, then Cigna changed his meds
Springfield News-Leader via Yahoo News· 2 years agoNearly a year-and-a-half ago, Mark Hall's ulcerative colitis was "in remission" and he was getting...
Can Biogen (BIIB) Navigate Multiple Challenges & Grow Again?
Zacks via Yahoo Finance· 2 years agoMost of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are...
Amgen (AMGN) Outperforms Industry Year to Date: What's Next?
Zacks via Yahoo Finance· 2 years agoAmgen's (AMGN) key drugs like Prolia, Repatha and Xgeva are driving sales. Amgen is also rapidly...
A Challenger to J&J's Top Blockbuster Is on the Way. Here's What You Need to Know.
Motley Fool· 1 year agoWhen you think of Johnson & Johnson (NYSE: JNJ), you may think of shampoo and Band-Aids. In fact,...
J&J (JNJ) Announces 2024 and Long-Term Financial Outlook
Zacks via Yahoo Finance· 6 months agoJohnson & Johnson JNJ announced sales and earnings growth expectations for 2024 and the 2025-2030...
Why Is Johnson & Johnson (JNJ) Down 0.2% Since Last Earnings Report?
Zacks via Yahoo Finance· 3 months agoIt has been about a month since the last earnings report for Johnson & Johnson (JNJ). Shares have...
Johnson & Johnson (JNJ) Down 2.2% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 1 year agoIt has been about a month since the last earnings report for Johnson & Johnson (JNJ). Shares have...
How AbbVie denied Americans access to fair competition for Humira
Quartz via Yahoo Finance· 1 year agoHumira, a monoclonal antibody used to treat arthritis among other conditions, is the most lucrative...
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
Motley Fool· 9 months agoOn average, healthcare stocks haven't kept up with the gains made by the rest of the market this year. Viatris (NASDAQ: VTRS), GSK (NYSE: GSK), and...
